Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Young-Chul Kim, In-Jae Oh, Keunchil Park, Sang We Kim, Byoung Chul Cho, Myung-Ju Ahn, Joo Hang Kim, Moon Ki Choi, Jong Seok Lee, Jin Seok Ahn
Publikováno v:
Lung Cancer. 119:36-41
Introduction Afatinib, an irreversible ErbB family blocker, approved for first-line treatment of epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC). This study investigated experience of afatinib within a comp
Autor:
William Pao, Matthias Freiwald, Vincent A. Miller, Scott N. Gettinger, Leora Horn, Vikram K. Chand, Egbert F. Smit, Bushi Wang, Harry J.M. Groen, D. Ross Camidge, Yelena Y. Janjigian, Jean Fan
Publikováno v:
Horn, L, Gettinger, S, Camidge, D R, Smit, E F, Janjigian, Y Y, Miller, V A, Pao, W, Freiwald, M, Fan, J, Wang, B, Chand, V K & Groen, H J M 2017, ' Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib ', Lung Cancer, vol. 113, pp. 51-58 . https://doi.org/10.1016/j.lungcan.2017.08.014
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Objectives In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutatio
Autor:
Silvia Ess, Thomas Cerny, P. Neumair, Florent Baty, Felicitas Hitz, M. Früh, Rene Warschkow, Martin Brutsche, Markus Joerger, L. Joos, Stephan Krähenbühl, A. Dutly
Publikováno v:
Lung Cancer. 100:38-44
Objectives Controversy exists about the integration of erlotinib in patients with EGFR wildtype, advanced NSCLC. Materials and methods We included patients with advanced NSCLC receiving at least two lines of palliative systemic treatment between Janu
Autor:
Dae Ho Lee, Sang We Kim, Minkyu Jung, Seok Yun Kang, Byoung Chul Cho, Hyo Sup Shim, Dong Wan Kim, Jin-Hyuk Choi, Jong Rak Choi, Dae Seog Heo, Joo Hang Kim, Heung Tae Kim, Sun Min Lim
Publikováno v:
Lung Cancer. 93:1-8
Objectives Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their synergistic activity in combination, we conducted a phase II study to determine t
Autor:
Junji Uchida, Nobuyuki Katakami, Kazumi Nishino, Jumpei Takeshita, Yoshinobu Namba, Kojiro Otsuka, Shiro Fujita, Masahide Mori, Akihiro Nishiyama, Satoshi Morita, Takako Okuyama, Yohei Korogi, Masahiro Iwasaku, Akito Hata, Hiroshige Yoshioka
Publikováno v:
Lung Cancer. 89:301-305
Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The aim of this study was to retrospectively evaluate the efficacy of e
Autor:
Masaki Nagashima, Kazuhiko Nakagawa, Atsushi Horiike, Tomohide Tamura, Haruyasu Murakami, Makoto Nishio, Masaru Sekiguchi, Hiroyasu Kaneda, Hidehito Horinouchi, Nobuyuki Yamamoto
Publikováno v:
Lung Cancer. 88(3):275-281
Objectives Human epidermal growth factor receptor 3 (HER3) is a key dimerization partner for HER family members and is associated with resistance to other HER family receptor-targeted therapeutics. This study evaluated the safety, tolerability, pharm
Publikováno v:
Lung Cancer. 88:223-230
Objectives Lung cancer accounts for a significant number of new cancer cases and deaths, with the majority of patients presenting with non-small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors are
Autor:
S. Bohnet, David F. Heigener, Martin Reck, Cornelius Kortsik, Joachim von Pawel, M.v. Eiff, W. Koester, Philipp A. Schnabel, K.M. Deppermann, Michael Thomas, Juergen R. Fischer
Publikováno v:
Lung Cancer. 84:62-66
Background Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less toxicity compared to conventional chemotherapy. This study was undertaken to determine whether Erlotin
Publikováno v:
Lung Cancer. 114:68-69
In patients with non-small cell lung cancer (NSCLC) progression with leptomeningeal (LM) metastases is a catastrophic event with limited treatment options. We report a patient who developed leptomeningeal disease while on front-line erlotinib. High-d
Autor:
Zhen Wang, Song Dong, Ben-Yuan Jiang, Ri-Qiang Liao, Hua-Jun Chen, Yi-Long Wu, Xu-Chao Zhang, Jian Su, Jin-Ji Yang, Chong-Rui Xu, Qiang Nie, Qing Zhou, Yi-Sheng Huang, Xue-Ning Yang, Wen-Zhao Zhong, Bin-Chao Wang, Hong-Hong Yan
Publikováno v:
Lung Cancer. 79:33-39
There is no published overview of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer (NSCLC). This study aimed to classify the diversity of EGFR-TKI failure, and to investigate